Welcome to our dedicated page for PLXP news (Ticker: PLXP), a resource for investors and traders seeking the latest updates and insights on PLXP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PLXP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PLXP's position in the market.
PLx Pharma Inc. (NASDAQ: PLXP) plans to release its third quarter financial results on November 12, 2021. The company focuses on its PLxGuard™ drug delivery platform, aiming to enhance drug absorption and minimize stomach injury risks. Its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, are FDA-approved liquid-filled aspirin capsules designed for better absorption and reduced stomach contact. CEO Natasha Giordano and CFO Rita O’Connor will host a conference call for results discussion at 8:30 a.m. ET on the same day, with a replay available for two weeks.
PLx Pharma Inc. (NASDAQ: PLXP) has successfully launched its VAZALORE™ liquid-filled aspirin capsules across 30,000 retail locations and e-commerce sites. The launch has garnered exceptionally positive feedback from consumers and healthcare professionals, with an expansion of its cardiovascular specialty field force to raise awareness. VAZALORE, which offers targeted release to minimize stomach contact, aims to serve over 40 million patients at risk of heart attacks and strokes. A third quarter earnings call is scheduled for November 12, 2021.
PLx Pharma Inc. (NASDAQ: PLXP) clarified recent media confusion regarding the US Preventive Services Task Force (USPTF) aspirin guidelines. The draft recommendations target primary prevention and do not apply to patients with a history of cardiovascular events, who continue to be advised to use aspirin.
PLx emphasizes that its product, VAZALORE, is designed for these patients, ensuring better stomach protection and reliable absorption compared to standard aspirin. Clinical trials indicate VAZALORE shows fewer gastric erosions than traditional aspirin.
PLx Pharma Inc. (NASDAQ: PLXP) announced that CEO Natasha Giordano and CFO Rita O’Connor will present virtually at two healthcare conferences. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 21, 2021, at 2:55 PM ET, followed by the 2021 Cantor Global Healthcare Conference on September 29, 2021, at 8:40 AM ET. Both presentations will be webcast live and archived for 30 days on the company’s website. PLx's lead product, VAZALORE, is an FDA-approved liquid-filled aspirin capsule that ensures faster platelet inhibition and reduces stomach risks.
PLx Pharma Inc. (NASDAQ: PLXP) announces the nationwide launch of its FDA-approved liquid-filled aspirin capsules, VAZALORE, available at major retailers and online. A national television advertising campaign will enhance visibility, targeting high-profile sports programming and popular networks. VAZALORE is designed to offer effective platelet inhibition while protecting the stomach, reducing risks of erosions and ulcers compared to traditional aspirin. This innovative product aims to support patients with vascular diseases and diabetes in aspirin therapy.
PLx Pharma Inc. (NASDAQ: PLXP) has announced the launch of VAZALORE, available in over 30,000 U.S. retail stores, including major retailers like Walmart and CVS. The company reported no revenue for Q2 2021, a decline from $27,907 in Q2 2020, while net loss expanded to $18.7 million, or ($0.79) per share, compared to a loss of $6.0 million in the previous year. Operating expenses increased significantly, with selling and marketing costs rising to $5.5 million. Despite these losses, PLx holds $80.2 million in cash and cash equivalents as of June 30, 2021, supporting its strategic initiatives.
PLx Pharma Inc. (NASDAQ: PLXP) announced that its FDA-approved liquid-filled aspirin capsules, VAZALORE, are set to launch in nearly 8,000 CVS stores. This includes three stock-keeping units (SKUs): VAZALORE 81 mg (12 count), VAZALORE 81 mg (30 count), and VAZALORE 325 mg (30 count), with CVS preparing to showcase them with 'Coming Soon' placeholders. This launch positions VAZALORE alongside other retailers such as Walmart and Walgreens, aiming to provide effective aspirin therapy while reducing the risk of stomach issues.
PLx Pharma Inc. (NASDAQ: PLXP) announced that its FDA-approved liquid-filled aspirin capsules, VAZALORE, will be available in over 2,400 Rite Aid stores starting August. Three SKUs, including VAZALORE 81 mg and 325 mg, will have 'Coming Soon' placeholders in stores to notify consumers. CEO Natasha Giordano expressed enthusiasm for the launch, noting the growing accessibility of this innovative aspirin therapy, which offers improved platelet inhibition and reduced gastrointestinal risks compared to traditional aspirin.
PLx Pharma Inc. (NASDAQ: PLXP) announced it will release its 2021 second quarter financial results on August 6, 2021, before U.S. markets open. A conference call hosted by CEO Natasha Giordano and CFO Rita O’Connor will provide insights into the results and business updates, starting at 8:30 a.m. ET. VAZALORE™, the company’s FDA-approved liquid-filled aspirin capsule, offers improved platelet inhibition and reduced risk of stomach issues compared to traditional aspirin, targeting patients with vascular disease and diabetes.
PLx Pharma Inc. (NASDAQ: PLXP) has announced that its FDA-approved liquid-filled aspirin capsules, VAZALORE, will be available in over 8,000 Walgreens stores starting in August 2021. The products include three SKUs: VAZALORE 81 mg (12 and 30 count) and VAZALORE 325 mg (30 count). With 'Coming Soon' shelf placeholders already in place, the partnership is seen as a significant milestone in PLx's commercial launch strategy. VAZALORE aims to offer faster and safer aspirin therapy compared to traditional options, targeting patients at risk of cardiovascular issues.
